Related references
Note: Only part of the references are listed.Measurement of Gamma Glutamyl Transferase to Determine Risk of Liver Transplantation or Death in Patients With Primary Biliary Cholangitis
Alessio Gerussi et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2021)
Primary biliary cholangitis with normal alkaline phosphatase: A neglected clinical entity challenging current guidelines
Benedetta Terziroli Beretta-Piccoli et al.
JOURNAL OF AUTOIMMUNITY (2021)
A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA
Jorn M. Schattenberg et al.
JOURNAL OF HEPATOLOGY (2021)
Association of bezafibrate with transplant-free survival in patients with primary biliary cholangitis
Atsushi Tanaka et al.
JOURNAL OF HEPATOLOGY (2021)
Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase
Carla F. Murillo Perez et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2020)
Real-World Effectiveness of Obeticholic Acid in Patients with Primary Biliary Cholangitis
Surain B. Roberts et al.
HEPATOLOGY COMMUNICATIONS (2020)
Biochemical and plasma lipid responses to pemafibrate in patients with primary biliary cholangitis
Satoru Joshita et al.
HEPATOLOGY RESEARCH (2019)
The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis
Michael Trauner et al.
HEPATOLOGY (2019)
A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis
C. Corpechot et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
NGM282 for Treatment of Patients With Primary Biliary Cholangitis: A Multicenter, Randomized, Double Blind Placebo Controlled Trial
Marlyn J. Mayo et al.
HEPATOLOGY COMMUNICATIONS (2018)
A 2-year multicenter, double-blind, randomized, placebo-controlled study of bezafibrate for the treatment of primary biliary cholangitis in patients with inadequate biochemical response to ursodeoxycholic acid therapy (Bezurso)
C. Corpechot et al.
JOURNAL OF HEPATOLOGY (2017)
Identification and Characterization of Fenofibrate-Induced Liver Injury
Jawad Ahmad et al.
DIGESTIVE DISEASES AND SCIENCES (2017)
Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study
David Jones et al.
LANCET GASTROENTEROLOGY & HEPATOLOGY (2017)
Long-Term Fenofibrate Treatment in Primary Biliary Cholangitis Improves Biochemistry but Not the UK-PBC Risk Score
Vinod S. Hegade et al.
DIGESTIVE DISEASES AND SCIENCES (2016)
Fibrates and cholestasis
Nisanne S. Ghonem et al.
HEPATOLOGY (2015)
Changing nomenclature for PBC: From 'cirrhosis' to 'cholangitis'
Ulrich Beuers et al.
JOURNAL OF HEPATOLOGY (2015)
LONG-TERM THERAPY WITH BEZAFIBRATE AND URSODEOXYCHOLIC ACID IS INSUFFICIENT FOR PREVENTING DISEASE PROGRESSION IN PATIENTS WITH ADVANCED PRIMARY BILIARY CIRRHOSIS
A. Reig et al.
JOURNAL OF HEPATOLOGY (2015)
Primary biliary cirrhosis
Elizabeth J. Carey et al.
LANCET (2015)
Fenofibrate is effective adjunctive therapy in the treatment of primary biliary cirrhosis: A meta-analysis
Alla Y. Grigorian et al.
CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY (2015)
Combination therapy of bezafibrate and ursodeoxycholic acid for primary biliary cirrhosis: A meta-analysis
Yan Zhang et al.
HEPATOLOGY RESEARCH (2015)
Early Biochemical Response to Ursodeoxycholic Acid and Long-Term Prognosis of Primary Biliary Cirrhosis: Results of a 14-Year Cohort Study
Li-Na Zhang et al.
HEPATOLOGY (2013)
Randomized controlled trial assessing the effect of simvastatin in primary biliary cirrhosis
William J. Cash et al.
LIVER INTERNATIONAL (2013)
Efficacy of fenofibrate in Chinese patients with primary biliary cirrhosis partially responding to ursodeoxycholic acid therapy
Xiao Feng Han et al.
JOURNAL OF DIGESTIVE DISEASES (2012)
Optimizing biochemical markers as endpoints for clinical trials in primary biliary cirrhosis
Njideka Momah et al.
LIVER INTERNATIONAL (2012)
Early primary biliary cirrhosis: Biochemical response to treatment and prediction of long-term outcome
Christophe Corpechot et al.
JOURNAL OF HEPATOLOGY (2011)
Baseline Ductopenia and Treatment Response Predict Long-Term Histological Progression in Primary Biliary Cirrhosis
Teru Kumagi et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2010)
Fenofibrate in Primary Biliary Cirrhosis: A Pilot Study
E. N. Liberopoulos et al.
OPEN CARDIOVASCULAR MEDICINE JOURNAL (2010)
Primary Biliary Cirrhosis
Keith D. Lindor et al.
HEPATOLOGY (2009)
Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis
Christophe Corpechot et al.
HEPATOLOGY (2008)
The efficacy of ursodeoxycholic acid and bezafibrate combination therapy for primary biliary cirrhosis: A prospective, multicenter study
Shinji Iwasaki et al.
HEPATOLOGY RESEARCH (2008)
Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid
A Parés et al.
GASTROENTEROLOGY (2006)
Prospective randomized crossover trial of combination therapy with bezafibrate and UDCA for primary biliary cirrhosis
J Itakura et al.
HEPATOLOGY RESEARCH (2004)
Cholestatic syndromes
M Trauner et al.
CURRENT OPINION IN GASTROENTEROLOGY (2003)
Simvastatin in primary biliary cirrhosis:: effects on serum lipids and distinct disease markers
U Ritzel et al.
JOURNAL OF HEPATOLOGY (2002)
The PPARs: From orphan receptors to drug discovery
TM Willson et al.
JOURNAL OF MEDICINAL CHEMISTRY (2000)